Credit Suisse Downgrades Medivation (MDVN) to Neutral; Sees Little Likelihood of Competing Bid
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Credit Suisse downgraded Medivation (NASDAQ: MDVN) from Outperform to Neutral with a price target of $81.50 after the company agreed to be acquired by Pfizer for $81.50 shares.
Analyst K. MacKay commented, "CS Special Situations Desk expects the deal to close with high probability, and we see little likelihood of a competitive bid following the lengthy auction process. Furthermore, we see little likelihood of anti-trust concerns given no overlap in the mechanisms of action of portfolio products. We therefore do not expect major upside / downside to MDVN's valuation and now focus on successful deal closure."
Shares of Medivation closed at $80.42 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Chipotle Mexican Grill (CMG) to Neutral; 'New Normal'
- RBC Capital Cuts Price Target on Pentair (PNR) to $66 Following 3Q Report
- Wedbush Cuts Price Target on Polaris Industries (PII) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!